The control of genotoxic impurities (GTIs) is a crucial activity that is performed for any new chemical entity intended for clinical use. A key element of this is the quality risk assessment. This article seeks to examine the primary components of such a strategy, focusing specifically on the effective use of in silico assessment tools to augment this process, in particular the calculation of theoretical purge factors based on the physicochemical properties of a specific GTI and its interrelationship to the process.
Regulatory requests that marketing authorization holders for chemically
synthesized active substances risk assess their medicines for the
potential presence of N-nitrosamines have led to
a renewed interest in amine nitrosation. We have used published mechanistic
and kinetic studies of amine nitrosation to assess the risk that traces
of nitrite in the water used during active pharmaceutical ingredient
(API) manufacturing could give rise to significant levels of N-nitrosamines. We conclude that the levels of nitrite typically
found in water used for API manufacture are very low (<0.01 mg/L)
and will not give rise to significant levels of N-nitrosamines through reaction with basic secondary amines (pK
a > 9.5) in the majority of cases. The use of
less basic amines, elevated processing temperatures, or low pH conditions
in combination with elevated levels of nitrite have the potential
to generate levels of N-nitrosamines that could lead
to significant quantities being present in the isolated API if the
downstream processing does not provide an adequate purge. The kinetic
models described may be used to risk assess specific situations or
processes. For example, the addition of traces of dimethylamine to
a nitrosation reaction is predicted to lead to the rapid, quantitative
formation of N-nitroso dimethylamine. Simple tertiary
alkylamines can nitrosate via a dealkylative process, which is significantly
slower than secondary amine nitrosation. Therefore, they do not represent
a risk of N-nitrosamine formation under conditions
where there is no significant risk of secondary amine nitrosation.
The present publication surveys several applications of in silico (i.e., computational) toxicology approaches across different industries and institutions. It highlights the need to develop standardized protocols when conducting toxicity-related predictions. This contribution articulates the information needed for protocols to support in silico predictions for major toxicological endpoints of concern (e.g., genetic toxicity, carcinogenicity, acute toxicity, reproductive toxicity, developmental toxicity) across several industries and regulatory bodies. Such novel in silico toxicology (IST) protocols, when fully developed and implemented, will ensure in silico toxicological assessments are performed and evaluated in a consistent, reproducible, and well-documented manner across industries and regulatory bodies to support wider uptake and acceptance of the approaches. The development of IST protocols is an initiative developed through a collaboration among an international consortium to reflect the state-of-the-art in in silico toxicology for hazard identification and characterization. A general outline for describing the development of such protocols is included and it is based on in silico predictions and/or available experimental data for a defined series of relevant toxicological effects or mechanisms. The publication presents a novel approach for determining the reliability of in silico predictions alongside experimental data. In addition, we discuss how to determine the level of confidence in the assessment based on the relevance and reliability of the information.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.